Trial Profile
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms ADAPT
- Sponsors United Therapeutics Corporation
- 03 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 31 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.
- 19 Sep 2022 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.